Medifast, Inc. (MED) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Medifast, Inc. operates a single reportable segment, OPTA VIA, which provides a coach-guided lifestyle system for metabolic health and weight management. The company reported a net loss for the quarter, driven by a significant decline in active earning coaches and revenue.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Revenue | $89.4 million | $140.2 million | $310.7 million | $483.5 million |
| Gross Profit | $62.2 million | $105.7 million | $223.0 million | $356.4 million |
| Gross Margin | 69.5% | 75.4% | 71.8% | 73.7% |
| Operating Income (Loss) | $(4.1) million | $2.1 million | $(6.4) million | $2.2 million |
| Net Income (Loss) | $(2.3) million | $1.1 million | $(0.6) million | $1.3 million |
| Diluted EPS | $(0.21) | $0.10 | $(0.05) | $0.12 |
| Cash & Equivalents | $99.5 million | (Balance Sheet Data) | ||
| Total Investments | $74.0 million | |||
| Working Capital | $161.1 million | (As of Sep 30, 2025) | ||
| Operating Cash Flow (9M) | $12.1 million | $29.4 million | (YTD Comparison) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 36.2% year-over-year in Q3 and 35.7% year-over-year for the nine months ended September 30, 2025. This is primarily attributed to a 35.0% drop in active earning OPTA VIA coaches (from 30,000 to 19,500) and a 1.9% decrease in revenue per coach.
- Profitability Shift: The company swung from a net income of $1.1 million in Q3 2024 to a net loss of $2.3 million in Q3 2025. Operating loss widened due to lower gross profit and a loss of leverage on fixed costs.
- Cost Structure: Cost of sales decreased 21.0% in Q3, driven by lower volumes, but was partially offset by a $1.6 million reserve for the reformulation of the Essential product line. SG&A expenses decreased 36.0% due to lower coach compensation and reduced marketing/convention costs.
- Investment Activity: The company sold its entire investment in LifeMD, Inc. during Q2 2025, realizing a $3.2 million gain in the nine-month period, which contributed to "Other income."
Guidance, Outlook, and Risks
- Strategic Focus: Management is executing a transformation focused on metabolic health, aiming to fuel coach productivity and growth. The strategy includes tailoring offerings for three client categories: habit-based programs, GLP-1 medication users, and those transitioning off GLP-1s.
- Product Innovation: The company plans to launch new product lines incorporating next-generation ingredients for metabolic enhancement in the coming year. A new "Premier+" auto-ship program was launched in July 2025 to improve coach compensation predictability.
- Market Risks: The filing highlights competition from GLP-1 medications, which are changing consumer behavior in the weight loss market. Macroeconomic factors, including inflation and potential tariffs, pose risks to raw material costs and consumer spending.
- Liquidity: The company maintains a strong balance sheet with $173.5 million in cash, cash equivalents, and investment securities. It terminated its credit agreement in October 2024 with no outstanding borrowings.
Investor Verification Checklist
- Coach Count Trend: Verify the sustainability of the 35% decline in active earning coaches and the effectiveness of new retention/acquisition initiatives (e.g., EDGE program).
- GLP-1 Impact: Assess the actual conversion rates of clients using GLP-1 medications into Medifast's coach-supported programs versus the theoretical market opportunity.
- Product Reformulation Costs: Monitor the impact of the $1.6 million reserve for the Essential product line reformulation on future margins and sales.
- Fixed Cost Leverage: Evaluate management's ability to reduce fixed costs further as revenue volumes remain depressed to restore operating margins.
- LifeMD Collaboration: Confirm the status of the ongoing collaboration with LifeMD post-investment sale and its impact on future SG&A expenses.